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Neurocognitive Dysfunction and 
Diabetic Foot
Caroline A. Fisher
Abstract
Diabetic foot ulcers are one of the most serious complications associated with 
diabetes. People with diabetes experience an accelerated rate of age-related cogni-
tive decline, and comorbid complications increase the likelihood of neurocognitive 
attenuation. The current body of research into neurocognitive functioning in 
individuals with diabetic foot ulcers is small, but suggests significantly increased 
rates of neurocognitive dysfunction, and that up to one quarter of this cohort have 
cognitive functioning consistent with dementia samples. This has implications for 
utilising disease self-management as the primary treatment model. Neurocognitive 
deficits mean that understanding, retaining, and adhering to management recom-
mendations are likely to be difficult in this group. Further research is needed in 
this area to determine the specific neurocognitive profile associated with diabetic 
foot, including which cognitive domains are the most impacted. The provision of 
a framework for tailoring management strategies to assist this group with more 
efficacious disease management is also required.
Keywords: cognition, diabetic, diabetic foot, neurocognitive functioning, 
neuropsychology, self-management, ulcers
1. Introduction
Diabetes mellitus is a disorder of insulin deficiency and is categorised into two 
types. The primary mechanism of disease in Type 1 is the loss of pancreatic islet 
β-cells [1], resulting in an inability to produce insulin. The typical trio of onset of 
symptoms for Type 1 are excess thirst, increased appetite, and excess urine produc-
tion, as well as overt hyperglycaemia [2]. The definitive cause of Type 1 diabetes 
is not known. However, it is believed that it is likely to be related to an immune 
or auto-immune system disorder in 70–90% of those affected (Type 1A), with 
remainder of cases considered idiopathic (Type 1B) [2]. Type 1 is most commonly 
diagnosed in childhood, although onset can occur at any age [2]. Type 1 is estimated 
to account for 5–15% of all cases of diabetes [1]. There is no cure for the condition 
and individuals with this disorder require the injection of insulin to survive [3].
Type 2 diabetes is generally triggered by a number of lifestyle factors including  
being overweight or obese, having a sedentary lifestyle and consuming a diet 
containing high amounts of processed and red meat, refined grains and drinks that 
are high in sugar [4]. It shares many of the symptoms of type 1, and also involves 
progressive pancreatic β-cell failure. The initial phases are characterised by changes 
in the bodies’ response to insulin and can later progress to insufficient insulin being 
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produced [3]. However, it has been indicated that the mechanisms that trigger 
β-cell death via cytokine and nutrient changes in Type 2 are different from those 
that occur in Type 1 [5]. In contrast to Type 1, Type 2 diabetes can be controlled by 
dietary changes and oral medication, but can require the need for the injection of 
exogenous insulin with progression and worsening of the disease [3].
Type 1 diabetes is the most common type in children, with Type 2 very rare 
in those under 30 years of age [3]. The onset of Type 2 diabetes most commonly 
occurs in adulthood and is the most prevalent type of diabetes. Rates of both types 
appear to be growing with a global rise in all forms of diabetes noted over the last 
40 years with the greatest magnitude of increase thought to be driven by adult Type 
2 cases [6, 7]. Thus, the health burden of diabetes is becoming more pronounced, 
increasing the strain on health systems and resulting in an upturn in diabetes related 
disease burden across the world.
1.1 Diabetes complications: foot ulcers
Diabetic foot ulcers are one of the most serious complications of the disease as 
they can lead to amputation [8], significantly increasing disease burden [9]. They 
are more common in people with peripheral arterial disease, and are generally 
caused by repeated pressure on an area that has high rates of vertical or sheer stress 
in people who suffer from peripheral neuropathy [10]. Healing of foot wounds 
can be slow, particularly if management guidelines are not followed, with 23% of 
wounds still present, after 12 months [11]. Foot ulcers can occur in people with 
both Type 1 and Type 2 diabetes. A recent systematic review indicated that the 
global rate of foot ulcers in people with diabetes is 6.3% [12]. Although variance 
in regional prevalence rates was found, with North America and Africa having the 
highest rates and Europe and Oceania the lowest [12]. Individuals who develop 
diabetic foot ulcers tend to have a longer duration of diabetic exposure, and higher 
rates of hypertension, diabetic retinopathy and smoking, but lower body mass 
indexes [12]. Diabetic foot ulcers occur prior to lower extremity amputations in 
around 84% of cases, and are associated with an increased risk of death by almost 
two and a half times, compared to people with diabetes without ulcers [13–15]. 
Research utilising a large Australian sample recently indicated a five-year mortality 
rate of 24.6% and a 10 year mortality rate of 45.4% in individuals treated at a multi-
disciplinary foot clinic for diabetic foot ulcers [16]. Foot ulcers are also consistently 
shown to be associated with a significant decrease in quality of life, impacting on 
many lifestyle areas including social functioning, employment, financial security, 
interpersonal relationships, psychological and physical health [17, 18].
1.2 Diabetes complications: neurological abnormalities
Despite being anatomically located at opposite ends of the body, foot ulcers and 
changes in brain functioning have a number of similar predisposing factors in indi-
viduals with diabetes. Co-occurring hypertension, diabetic retinopathy and current 
smoking are correlated with higher rates of neurological abnormalities observed 
through brain imaging in people with diabetes [19–21]. A systematic review of the 
diabetes brain imaging literature by van Harten et al. in 2006 included 55 studies 
the majority with predominantly middle age to early elderly cohort [22]. The review 
indicated that lacunar infarcts and cerebral atrophy are associated with diabetes, 
but that an association with white-matter lesions was unclear, due to the poor qual-
ity of the available studies in detecting subtle abnormalities of this kind. A narrative 
review from 2014 suggested that Type 1 diabetes was associated with small altera-
tions in brain volume in specific areas, including frontal, temporal and posterior 
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cortical areas, as well as subcortical grey matter [23]. These changes appear to occur 
early, with volumetric changes in Type 1 diabetes detectable, relative to controls, in 
childhood. In Type 2 diabetes volumetric loss is also observed but tends to be most 
commonly found in cortical and subcortical areas surrounding the ventricles [23]. 
While smaller hippocampal volumes have been found, this has generally been com-
mensurate with the magnitude of total volume loss, and thus specific atrophy of 
hippocampal areas (which have relevance to memory) in diabetes is not definitive.
A recent a systematic review of dynamic brain imaging investigated task and 
resting-state fMRI functional magnetic resonance imaging (fMRI) in diabetes. 
It concluded that reductions in the default mode network (DMN) connectivity 
are associated with diabetes [24]. The DMN is the brain network that is engaged 
when individuals are not actively participating in task-based pursuits (i.e. ‘at rest’). 
Findings of abnormal network activity during task based studies were reported to 
be less consistent, with some studies reporting reduced brain activation in brain 
areas related to the task, and others over activation [24]. Neurological changes in 
diabetes have relevance to neurocognitive functioning and this association will be 
explored further in Section 2.2.
1.3 Diabetes self-management
The impact of diabetes on health, wellbeing and functioning can be seen, from 
head to toe, with the effect of non-optimal management of the disease having 
significant implications for quality of life and morbidity. The importance of 
diabetes self-management has been promoted within the field as a means to assist 
individuals with diabetes to manage their condition effectively and minimise 
complications [25–28]. Best practice self-management support has been identified 
as including; education about diabetes and treatment options; managing nutrition 
and exercise as part of on-going lifestyle changes; utilising prescribed medications 
safety to maximise their therapeutic efficacy; self-monitoring of factors such as 
blood glucose levels and using effective decision making to interpret the results; 
employing strategies to manage complications, detecting these when they do arise 
and treating them early and appropriately; identifying and managing psychosocial 
issues; and developing strategies to promote health and behaviour change that 
will be effective for the individual [25]. Many of these self-management strategies 
require a range of higher level cognitive skills to be implemented and maintained 
consistently. However, neurocognitive attention is associated with the disease, and 
neurocognitive difficulties may impact on the capacity of individuals with diabetes 
to effectively implement disease self-management strategies.
2. Neurocognitive functioning in diabetes
Neurocognitive abilities are localised in the brain and encompass a broad 
range of thinking skills including attention, concentration, processing speed, new 
learning and memory, language, planning, organisation, problem solving and 
visual-perceptual and spatial abilities. In addition to looking at skills in specific 
neurocognitive domains, overall measures of ability, such as intellectual assess-
ment (IQ ) can also be conducted to provide information about general cognitive 
functioning. Neurocognitive skills impact on daily living and deficits can effect an 
individual’s functional and vocational capacity. Neurocognitive deficits are defining 
features of a number of neurological cognitions, including dementia and traumatic 
brain injuries, and the assessment and management of these difficulties falls within 
the specialty of clinical neuropsychology.
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2.1  Theory of neurocognitive functioning across the lifespan in diabetes  
and complications
There is a relatively large body of literature that has investigated the impact of 
diabetes on neurocognitive functioning. In 2008, Biessels and colleagues hypoth-
esised a framework for conceptualising the impact of diabetes on neurocognition, 
across the lifespan [3]. Following a thorough review of the literature available at the 
time, they proposed two age-related time point vulnerabilities for diabetes to detri-
mentally impact on neurocognitive functioning, with additional further increased 
risk observed in individuals with high levels of co-morbid diabetes related compli-
cations. Biessels et al. proposed that the first time period for cognitive attenuation 
vulnerability was during the period of neuronal maturation and brain development 
in childhood [3]. They suggested that those children who developed Type 1 dia-
betes at a younger age (i.e. between 5 and 7 years) were at higher risk of showing 
attenuated cognitive development, compared those who developed Type 1 later in 
childhood. The second age-related period of increased vulnerability to cognitive 
attenuation was proposed to occur at the time point were normal age-related cogni-
tive decline begins across several cognitive domains, in middle age. Biessels et al. 
suggested that individuals with diabetes in middle and older age (predominantly a 
Type 2 cohort) are likely to show an accelerated rate of cognitive decline, relative 
to their age matched peers [3]. Diabetes related co-morbidities were proposed as a 
third variable that increased the risk of cognitive attenuation in diabetes cohorts. 
The primary conditions posited in this area were microvascular disease, severe 
hypoglycemic episodes, and hypertension [3].
The hypothesis outlined by Biessels et al. [3], continues to hold merit since 
it was first proposed, with subsequent findings that have been published in the 
last 10 years largely supporting this framework. Longitudinal data from Type 1 
diabetes research (following individuals with childhood diagnoses through to 
youth, at 12 years follow-up) has indicated that early onset is associated with poorer 
sustained attention, divided attention, new learning, and mental efficiency [29]. 
Longitudinal data from ageing studies has indicated that in middle aged cohorts 
accelerated cognitive decline is observed in those who had Type 2 diabetes at study 
baseline, relative to non-diabetes age-matched peers [30]. Additionally, incident 
diabetes (those who go on to develop diabetes but have not been diagnosed at base-
line) showed subtle early decline in information processing speed, which became 
more pronounced following diagnosis and with increasing duration of illness [30]. 
The Biessels et al. proposal [3] that higher rates of diabetes complications increases 
the risk of cognitive decline has also been supported, with several studies showing 
greater rates of neurocognitive attenuation in people with diabetes who also have 
hypertension, neuropathy, retinopathy [30–32].
Recent research has also indicated a link between diabetes, neurocognitive 
decline and dementia, and that the link may be stronger in women [23, 33–35]. The 
primary dementia syndromes associated with diabetes are Alzheimer’s disease and 
vascular dementia. It has been suggested that the neuropathogenesis in diabetes and 
Alzheimer’s disease may be related, and that the increased burden of small-vessel 
disease in diabetes can contribute to the development of a vascular based dementia 
[23, 33]. Dementia, as defined under the Major Neurocognitive Disorder framework 
within Diagnostic and Statistical Manual of Mental Disorders, is primarily a disor-
der of neurocognitive dysfunction [36]. As such, it is not surprising that capacity 
for disease self-management in people with diabetes and co-occurring dementia is 
diminished [33]. It has been posited that there is a bidirectional impact, whereby 
poor self-management, due to cognitive impairment from dementia, leads to poorer 
diabetes control, increasing the likelihood of further cognitive impairment [33].  
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As such, further investigation is needed into how to specifically target education 
and management strategies in this group, as they may not be able to utilise these in 
the same way as those with stronger neurocognitive functioning.
2.2 Neurocognitive profile in diabetes
Not all studies separate Type 1 and Type 2 diabetes cases when investigating 
neurocognitive functioning in adults. Where the types have been looked at indi-
vidually, or in studies where the research has demarked the groups discretely, there 
are both similarities and differences in the profile of cognitive attenuation [37]. 
A systematic review of the Type 1 literature was conducted in 2005 and included 
33 studies [38]. This review indicated that Type 1 diabetes is associated with 
attenuation in functioning on overall intelligence measures, as well as attention, 
psychomotor processing speed, cognitive flexibility and visual-perceptual and 
spatial functioning at the domain level [37, 38]. Notably however, the mean age of 
participants in studies included in this review most commonly fell in the 30s, with 
the oldest mean age of 47.6 years. Thus, the review data was mainly comprised of 
younger adult cohorts, and relatively little is known about the Type 1 neurocogni-
tive profile in middle aged and older adults.
Type 2 diabetes cohorts show some similarities in their neurocognitive 
profile to Type 1. They exhibit attenuation in their processing speed, attention 
and executive functioning, but tend show a greater magnitude of decrement 
in memory functioning compared to Type 1 [30, 37, 39]. There is presently no 
seminal, overarching systematic review and meta-analysis that has attempted 
to synthesise the evidence base regarding cognitive functioning in adults with 
Type 2 diabetes, relative to controls, across all major neurocognitive domains. 
The most comprehensive attempt to integrate the literature was a meta-analysis 
published by Palta and colleagues in in 2014. This meta-analysis looked at neuro-
cognitive functioning in six areas, across 24 studies with a total of 3351 patients 
with diabetes [40]. The included studies were predominantly from western 
countries, and there was a relatively large age range between the studies with 
means in the late 50s to early 80s. The results indicated that at a domain level, 
the largest effect size for diabetes status was seen in the areas of motor function 
(d = −0.36), executive function (d = −0.33) and processing speed (d = −0.33), 
followed by verbal memory (d = −0.28), visual memory (d = 0.26) and attention/
concentration (d = −0.19). Specific neurocognitive tests were also identified that 
were most likely to demonstrate diabetes related cognitive attenuation. These 
included the dominant hand condition on the Grooved Pegboard, immediate 
recall on the Rey Auditory Verbal Learning Task, trails A and B from The Trail 
Making Test, delayed recall from the Rey-Osterreith Complex Figure task, and 
part 1 of the Stroop task. The research team did note, however that they were 
unable to stratify the results according to age, could not make any comments in 
regard to gender, and also noted that the results may not be representative across 
different ethnicity groups.
Task based fMRI studies have indicated that alterations in activation networks 
may be correlated with performance levels on neuropsychological assessment [24]. 
There is some evidence that poorer memory performances are seen in individu-
als with diabetes who have reduced activation in the default mode network [41]. 
Reduced speed on a complex trail making activity requiring set-shifting (trails B) 
and complex figure delayed recall has been associated with neural abnormalities in 
the cuneus and lingual gyrus, areas associated with inhibitory control and visual 
memory [42]. Thus, there is some evidence linking functional brain activation 
changes and poorer neuropsychological functioning in this population.
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3. Neurocognitive functioning in individuals with diabetic foot ulcers
Relative to the general diabetes literature, fewer research studies have been 
conducted that have investigated neurocognitive functioning specifically in people 
with diabetes and foot ulcers [43–46]. The research that is available appears to 
indicate attenuated functioning, at a group level, and significant impairments in 
a proportion of patients. This section of the chapter reviews what is known about 
neurocognitive functioning in people with diabetic foot ulcers and provides sugges-
tions for future research.
3.1 Cognitive screening and diabetic foot
Cognitive screening measures are short, easy to administer assessments that 
provide an overall measure of basic cognitive functioning. They generally require 
limited or short-duration training to administer and are utilised by a wide range of 
clinical disciplines. One of the most commonly administered cognitive screening 
measures is the Mini Mental State Examination (MMSE) [47]. A study by Marseglia 
et al. [43] utilised the MMSE to investigate cognitive functioning in a moderately 
sized cohort (n = 153) of individuals with diabetic foot complications. The sample 
was predominantly male (75.8%). The mean age of the cohort was 65 years (SD 
10.5) and the authors further sub-grouped this cohort into patients aged under 
65 years (n = 73) and those aged over 65 years (n = 80). HbA1c levels were reported 
at a mean of 7.7 (SD 1.4). The medium length of diabetes duration was 20 years, and 
a high proportion (70.6%) had undergone amputation.
In the Marseglia, et al. study [43] the mean MMSE score was found to be 24.6 
(SD = 3.6), with a range of 11–30. The authors used the cut-off score derived by 
Kivipelto et al. [48], with scores ≤24 defined as being indicative of general cognitive 
function impairment. Using this criterion, 39% of the total sample demonstrated 
cognitive impairment. The was a significant difference by age stratification with 
25% of the patients below 65 years showing impairment, compared to 53% of those 
above 65 years. Logistic regression indicated that foot amputation was associated 
with lower MMSE scores. No information was provided about which items/domains 
within the MMSE assessment were more commonly impaired. However, a small 
range of additional cognitive assessment measures were also employed in this study, 
and these will be reported, by domain, in Section 3.2.
A recently published study by Corbett and colleagues investigated neurocogni-
tive functioning in individuals with diabetic foot ulcers using a newer, and increas-
ingly widely used, cognitive screening measure, the Montreal Cognitive Assessment 
(MoCA) [45]. The like the MMSE, the MoCA is a quick (5–10 min) assessment 
tool that provides an overview of cognitive functioning, and is designed to detect 
cognitive decline. The MoCA provides better coverage of executive functioning, 
and higher-level language and visuospatial processing, relative to the MMSE, and 
produces less of a ceiling effect (i.e. is harder overall) [49]. The study by Corbett 
et al. [45] reported on MoCA and Patient Interpretation of Neuropathy (PIN) data 
in 30 patients with diabetic foot ulcers admitted to a specialist hospital unit for 
inpatient management of their foot wounds. The mean age of the study cohort was 
later middle age (m = 58.37 years, 10.64 SD), and the sample predominantly male 
(83%). Most of the cohort had type 2 diabetes (93%) of between 1 and 38 years 
duration (mode 10 years). The mean HBA1C level was 9.27 (SD 2.45), and there 
were high rates of macrovascular disease (60%) and hypertension (47%), moderate 
rates of nephropathy (27%) and retinopathy (23%). Thus, the cohort was younger 
than in the Marseglia et al. [43] study, but with poorer diabetes control, based on 
HbA1c results.
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The education corrected total mean MoCA score in the Corbett et al. [45], study 
was 22.37 (SD 3.65), and range 12 to 27, with no patients achieving a full score of 
30/30. Recommended MoCA cut-off scores to demark mild cognitive impairment 
vary from study to study [50–53]. Thus, the authors provided the percentages of 
participants below the full range of suggested cut-of values. A total of 87% of the 
cohort fell below the stringent cut-off criteria of <27, a further 77% below <26 and 
43% below <23. Further, 27% of the sample had a total MoCA score of <20. This 
indicates that more than one quarter of diabetic foot ulcer patients in this study 
had a MoCA score consistent with diagnosed dementia cohorts [52, 53]. When 
separated into individual cognitive areas, patients most commonly made errors on 
items assessing short-term recall (90%), executive functioning (87%) and language 
(77%), while in contrast items assessing orientation showed the highest degree of 
accuracy (90% scoring full marks).
The results of this study also reported on patients’ interpretations of their 
neuropathy on the PIN. Correlation analysis indicated that patients with higher 
MoCA scores provided more accurate responses on the Acute Foot Ulcer Onset PIN 
subscale. This subscale measures knowledge about how foot ulcers can develop. 
Thus, individuals with diabetic foot ulcers and lower cognitive functioning may 
have reduced understanding of how foot wounds occur.
The Australian MoCA results from the Corbett et al. [45] study can be further 
compared with existing studies that have used the MoCA for cognitive screening 
assessment in other diabetes cohorts [31, 54, 55], see Table 1. Participants in one 
of the comparison studies were Japanese inpatients receiving training on diabetes 
management [31], in another they were Canadian patients at diabetes educa-
tion clinics [55], and in the third it is not reported where the Turkish subject 
group were recruited from [54]. In each comparison study foot ulcer status was 
not commented on, but prevalence could be expected to parallel that of global 
estimates of foot ulcers in people with diabetes at around 6%, with a range 
between 2 and 14% consistent with prevalence rates found in each of the study 
countries [12].
The results displayed in Table 1 suggest that cognitive attenuation in diabetic 
foot ulcer individuals exceeds expectation, based on their diabetes status and 
age. The mean MoCA scores obtained by individuals with diabetic foot ulcers in 
the Corbett et al. [45] study were higher than those reported by Ozcan et al. [54] 
However, the mean age of the Ozcan et al. [50] study group was 13 years older. The 
Corbett et al. [45] MoCA results were similar to the Mori et al. [31] results—a group 
that had comparable HbA1c scores but a higher mean age, by 9 years. Compared to 
the cohort with the closest age match, Alagiakrishnan et al. [55] the Corbett et al. 
[43] MoCA results were notably lower.
Lead author,  
study year
Ozcan, 2014 Mori, 2015 Alagiakrishnan, 2013 Corbett, 2019
Mean age (SD) 71.27 (8.57) 67.3 (9.9) 59.9 (7.1) 58.37 (10.64)
Sample size 15 29 30 30
Mean HbA1c (SD) N/A 9.6 (1.8) N/A 9.27 (2.45)
Foot ulcer status N/A N/A N/A 100%
MoCA mean (SD) 15.53 (6.18) 22.87 (3.80)* 26.45 (2.72)* 22.37 (3.65)
*Total cohort Mean and SD calculated from pooled MCI present and MCI absent groups.
Table 1. 
Comparison of MoCA Cognitive Screening scores in Older Diabetes Cohorts.
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3.2 Neuropsychological assessment and diabetic foot
Screening measures such as the MoCA and similar measures like the MMSE 
are useful as quick and easy to administer assess ments, providing an overview 
of cognitive functioning [56]. They are designed to identify patients who may be 
experiencing cognitive decline but are limited in their capacity to pin-point specific 
cognitive deficits and the magnitude of neurocognitive attenuation, relative to 
estimated premorbid cognitive functioning. Neuropsychological assessments are 
the gold standard for eliciting this type of in-depth information on neurocognitive 
functioning, and ideally, where access is available, individuals with reduced scoring 
on cognitive screening measures should be referred for neuropsychological assess-
ment to accurately quantify cognitive deficits and provide information about likely 
causes of the cognitive dysfunction.
Notably, there are few studies that have used specialised and specific neuro-
psychological assessment measures in patients with diabetic foot complications. 
The Marseglia et al. [43] MMSE study described above, utilised a small number of 
focussed neuropsychological assessment tasks, in addition to cognitive screening, 
in their predominantly male, diabetic foot cohort. This included the Trail Making 
Test A & B assessing processing speed and mental flexibility, the Rey Auditory 
Verbal Learning Test assessing verbal memory and Ravens Coloured Progressive 
Matrices assessing visual reasoning skills. The overall group means, and their devia-
tion from expected premorbid or average age-matched norms, were not reported. 
However, age stratified data was provided and indicated that mental flexibility/
set shifting, short-term verbal recall, processing speed and visual abstract reason-
ing were poorer in participants over 65 years of age. Logistic regression of disease 
factors indicated that HbA1c levels correlated with verbal memory difficulties in all 
patients, and that concurrent microvascular complications, and prior amputation 
was associated with verbal memory attenuation in patients over 65 years of age.
A further study by Kloos et al., attempted to determine if there was an associa-
tion between foot ulcer relapse rate and cognitive impairment in 59 people with 
diabetes and previous foot ulcers [44]. The authors found no association between 
cognitive performance and re-ulceration at 1 year follow-up. However, a very 
limited number of neuropsychology tasks were employed in this study, assess-
ing functioning only in the areas of vocabulary knowledge, perceptual logic and 
processing speed. There were no tasks assessing attention, memory or executive 
functioning. The follow-up period was also relatively short at 12 months, and no 
information was provided about re-ulceration in the three patients who died during 
the follow-up period.
The most comprehensive study to investigate neurocognitive functioning in 
diabetic foot patients using a broad assessment battery was undertaken by Natovich 
and colleagues in 2016 [46]. To date, this is the only published study that has used 
a wide-range multi-domain neuropsychological assessment battery to investigate 
neurocognitive functioning specifically in a diabetic foot ulcer cohort. This study 
investigated neurocognitive functioning in a group of 99 individuals with diabetic 
foot ulcers, along with a comparison group of 95 people with type 2 diabetes 
without foot ulcers. The study design incorporated the use of a computerised cogni-
tive testing battery, NeuroTrax, with two more commonly used pencil and paper 
cognitive assessment tasks (Digit-symbol substitution task from the Wechsler Adult 
Intelligence Scale, WAIS; and a verbal fluency task).
The two late-middle aged study groups in Natovich et al. [46] were broadly 
matched on demographic and health related factors. This included gender ratio 
(predominantly male), smoking status and depressive symptoms. However, the 
non-foot ulcer group were slightly older, more highly educated, and had better 
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diabetes control than their foot-ulcer counterparts, including significantly lower 
HbA1c scores, and lower hypertension, retinopathy, neuropathy, nephropathy and 
microvascular disease prevalence.
The neurocognitive test results from this study were age and education adjusted, 
in order to mitigate any impact of the mild cohort imbalances in these demographic 
factors [46]. The results on the NeuroTrax battery and additional pencil and paper 
tasks indicated significantly poorer cognitive functioning in participants with foot 
ulcers, compared to the non-foot ulcer group, across all activities assessing cur-
rent cognitive functioning. This included scores in domains described as memory, 
attention and concentration, reaction time, executive functioning (with the 
description indicating predominantly a task of response inhibition), psychomotor 
speed, verbal fluency (phonemic and semantic), digit-symbol substitution, and 
global cognitive score (mean of domains, minus non-verbal intelligence). Post hoc 
adjustment for multiple comparisons was not reported in the study paper. However, 
when a Bonferroni correction is applied to the data, these group differences remain 
significant (i.e. p < 0.005). The only task on which a significant difference was not 
observed, was that estimating premorbid cognitive functioning (i.e. cognitive skills 
prior to any acquired neurocognitive impairment). It was further reported that 
global cognitive scores of the foot ulcer group differed significantly, from their esti-
mated premorbid functioning, while the non-foot ulcer group did not. This appears 
to indicate generalised cognitive attenuation in the foot ulcer group.
A second important factor to consider from the data reported in the Natovich 
et al. [46], study is the magnitude of the differences between the foot ulcer group 
scores in each of the cognitive areas, relative to their estimated premorbid baseline. 
The results were normalised to a standard distribution (i.e. a mean score of 100–
50th percentile, and standard deviation of 15–34 percentile ranks). The estimated 
premorbid cognition score for the foot ulcer group is reported as 96.78, which places 
at the 42nd percentile. None of the current cognitive functioning scores for the 
foot ulcer group were close to matching this. The current functioning score means 
ranged from as low as the 4th percentile (standard score of 72.77) for phonemic 
verbal fluency, to the 30th percentile (standard score of 91.76) for reaction time, 
with all but two results falling in the lowest quartile of functioning, for the age 
group. This contrasted with the non-foot ulcer group where the biggest percentile 
difference with premorbid cognition was 16 percentile ranks (standard score of 
94.16 verses 100.19; 34th verses 50th percentile). With six out of the nine cognitive 
areas reported scoring within 5 percentile ranks of the premorbid estimate for this 
group. This indicates that attenuation in cognitive functioning in the foot ulcer 
group is at magnitudes of clinical significance for all cognitive areas, and likely to 
represent significant impairment in a number of individuals. The results also show 
the cognitive attenuation is generalised across areas and occurs relative to estimated 
premorbid abilities, age-matched normative data, and non-foot ulcer diabetic peers.
This study is a useful addition to the literature, as the first to examine neu-
rocognitive functioning in a relatively comprehensive way, in a medium to large 
sample of individuals with diabetic foot ulcers. The researchers also attempted to 
match the sample, as closely as possible, with a non-foot ulcer diabetes comparison 
group. However, there are several limitations of the Natovich et al. study [46]. 
The first is the use of a less commonly used computerised measure of cognitive 
functioning, NeuroTrax. Although this measure has been reported on since 2003 
the program appears to have been developed on a small normative sample, and its 
applicability outside studies of mild cognitive impairment and Parkinson’s disease 
remains unclear [57, 58]. It is also unclear from the Natovich paper [46] exactly how 
NeuroTrax assesses functioning in each of the cognitive areas reported. For exam-
ple, it is not clear what form the memory assessment takes (e.g. word list learning, 
Diabetic Retinopathy
10
narrative stories, paired associates), and this limits its comparability to other 
neuropsychological and diabetes research. It would have also been useful for the 
authors of this study to have provided information about the percentage individu-
als with neurocognitive dysfunction pronounced enough to meet the criteria for 
dementia. An additional limitation is the data in the study are taken from a single 
cross-sectional time point. The field would significantly benefit from research that 
takes a longitudinal approach to cognitive functioning in individuals with diabetic 
foot ulcers to determine if the development of cognitive attenuation precedes the 
development of foot ulcers, or vice-versa.
3.3 Theoretical framework of neurocognitive dysfunction in diabetic foot
The results from the Natovich et al. [46], study appear to support the earlier 
hypothesis proposed by Biessels and colleagues [3], of cognitive ageing and diabetes 
comorbidities acting as correlating or catalytic factors for diabetes related cognitive 
deterioration. The foot ulcer group in the Natovich et al. [46] study had a mean age 
of 58.04 years (SD 6.87). Research indicates that normal age related cognitive decline 
is demonstrated from as early as 45 years onwards, and most prominently occurs in 
the cognitive areas of visual spatial ability, processing speed, and fine motor skills 
[59]. Further, the foot-ulcer group had a considerably higher level of diabetes disease 
burden and comorbidity relative to the non-foot ulcer diabetes comparison group, 
with higher HbA1c scores, and significantly increased rates of retinopathy (51.5% vs. 
9.5%), neuropathy (88.9% vs. 15.8%), nephropathy (33.3% vs. 3.2%) and micro-
vascular disease (88.9% vs. 51.6%). The results of the cognitive screening study by 
Corbett et al. [45] also support the idea proposed by Biessels et al. [3], with cognitive 
attenuation seen above expectation for age in a late 50s cohort of diabetes foot ulcer 
patients, with high rates of comorbidity including hypertension, retinopathy and 
neuropathy. Thus, diabetic foot wounds could be argued to be an important risk 
variable for cognitive decline in middle-aged people with diabetes.
In Figure 1, a graphical representation has been provided to visually illustrate 
the impact of diabetes, across the lifespan, for Type 1 diabetes, Type 2 diabetes, and 
people with diabetic foot complications, relative to normal functioning. The graph 
provides a representation of generalised cognitive proficiency (summed across 
cognitive domains) and illustrates what is known about neurocognitive functioning 
Figure 1. 
Neurocognitive functioning across the lifespan.
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in each of the groups, based on the currently available literature. Further research 
is needed to definitively characterise the magnitude of neurocognitive decline in 
individuals with diabetic foot ulcers, and also to determine if there are any differ-
ences in the rates and types of decline in Type 1 versus Type 2 suffers. Additional 
research would also be beneficial into neurocognitive functioning in Type 1 cohorts 
into middle and older age, as currently there are few studies that include Type 1 
patients in these age groups.
3.4 Self-management
The available neurocognitive functioning results in diabetic foot ulcer 
samples raise a number of concerns about the capacity of this group to effectively 
implement self-management practices. Self-management requires the ability to 
adequately understand, process and recall recommendations, as well as to con-
sistently implement these effectively in daily life. Given the rates of pronounced 
cognitive decrement that appear to be present in a number of diabetic people with 
foot wounds, it could be expected that a sizable proportion of this cohort may lack 
the capacity to do this. Interestingly, in 2017 a second study was published by the 
Natovich lead study group, that compared adherence to self-care in two diabetes 
samples, those with and without foot ulcers [60]. Although not specifically stated 
by the authors, this study appears to have utilised the same cohort of participants 
and controls to their neurocognitive study, described above [46], as the reported 
sample numbers and demographic details of participants are the same. This study 
employed the Summary of Diabetes Self-Care Activity self-report scale as well as 
two objective measures of diabetes control and adherence (BMI and HbA1C levels). 
The results indicated that individuals with foot ulcers were more adherent to blood 
tests, but less adherent to physical activity recommendations and had poor glycae-
mic control (HbA1c). The authors speculated that this may be due to difficulty in 
linking problematic glycaemic test results to changes in actual behaviour, as a result 
of cognitive impairment. They also suggested that the reduced physical activity 
in the foot-ulcer group may make glycaemic levels more difficult to control. The 
cognitive screening study by Corbett and colleagues [45] indicated that individu-
als with foot ulcers and lower cognitive functioning had reduced understanding 
of how foot wounds occur, relative to cognitively higher functioning participants. 
It would be interesting for this to be investigated further to determine if these 
individuals are at higher likelihood of experiencing poorer wound healing and 
re-ulceration in the future.
4. Conclusion
The available evidence indicates that neurocognitive dysfunction in individu-
als with diabetic foot ulcers is more pronounced than expected, for both their age 
and diabetes status. Thus, diabetic foot complications appear to be associated with 
cognitive impairment. The mechanistic causes of this dysfunction is likely to be 
related to the overall poorer diabetes control in this group, including higher HbA1c 
scores, and higher rates of hypertension, retinopathy, neuropathy, nephropathy and 
microvascular disease, relative to diabetes peers without foot ulcers. Many of these 
complications have been found to contribute to an increase in the prevalence of 
vascular dementia and Alzheimer’s disease in people with diabetes. Thus, cognitive 
impairment in this group may represent disease burden caused by a combination 
of glycaemic and vascular factors, leading to accelerated neuronal death. Cognitive 
impairment may contribute to a ‘vicious cycle’ reducing the capacity of people 
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to effectively self-manage their diabetes and foot health, which in turn results in 
poorer diabetes control and an increase in complications, leading to further attenu-
ation in cognitive functioning.
More research is needed to provide further information about the cognitive 
profile of individuals with diabetic foot ulcers, using a large battery of commonly 
utilised clinical neuropsychology assessment measures. The four existing studies 
have provided some useful initial information. However, additional work clearly 
outlining the specific domains of cognitive impairment, and the magnitude of 
this impairment, using commonly utilised neuropsychological tests, is required. 
Longitudinal research to determine whether cognitive decline increases over time 
in this group would be useful. Combining cognitive functioning measures with 
neuroimaging in the same cohort would also help to determine if cognitive impair-
ment is associated with observable neurological abnormalities. Including psycho-
logical factors, such as the high frequency mental health conditions of depression 
and anxiety, as well as diabetes distress ratings, would provide information about 
whether psychological factors also impact on cognitive functioning, and potentially 
treatment adherence in this group.
Routine cognitive screening is likely to be beneficial in individuals with diabetic 
foot ulcers, as the available evidence indicates a high proportion will have cogni-
tive dysfunction. Where available, individuals showing moderate to significant 
difficulties on screening measures should be referred for clinical neuropsychologi-
cal assessment, to quantify the magnitude and specific nature of their cognitive 
difficulties. Neuropsychologists can also provide an individualised plan for cogni-
tive remediation and management strategies to assist with cognitive difficulties in 
daily life. This may assist in improving effective self-management compliance and 
improve over outcomes in his group.
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